___

• Slamon DJ, Leyland-Jones B, Shak S, et al. Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2. N Engl J Med 2001; 344: 783- 92.
• Chu TF, Rupnick MA, Kerkela R, et al. Cardiotoxicity associated with tyrosine kinase inhibitor sunitinib. Lancet 2007; 370: 2011-9.
• Veronese ML, Mosenkis A, Flaherty KT, et al. Mechanisms of hypertension associated with BAY 43-9006. J Clin Oncol 2006; 24: 1363-9.
• Rini BI: Quantifying hypertensionin patients with cancer treatd with sorafenid. Lancet Oncol 2008; 9: 86-7.
• Khakoo AY, Yeh ET. Management of cardiovascular disease in patients with cancer and cardiac complications of cancer therapy. Nat Clin Pract Oncol 2008; 5: 655-67.
• Senkus E, Jassem J. Cardiovascular effects of systemic cancer treatment. Cancer Treat Rev. 2010, doi: 10.1016/j.ctrv 2010: 11.01.
• Iarussi D, Indolfi P, Casale F, Coppolino P, Tedesco MA, Di Tullio MT. Recent advances in the prevention of anthracycline cardiotoxicity in childhood. Curr Med Chemistry 2001; 8: 1649- 60.
• Outomuro D, Grana DR, Azzato F, Milei J. Adriamycine- induced myocardial toxicity: New solutions for an old problem? Int J Cardiol 2007; 117: 6-15.
• Krause DS, Van Etten RA: Tyrosine kinase as targets for cancer therapy. N Engl J Med 2005; 353: 167-72.
• Maitland ML:Cardiovascular toxicol of new agents. Clin Adv Hematol Oncol 2008; 6: 657-9.
• Sica DA: Angiogenesis inhibitors and hypertension:an emerging issue. J Clin Oncol 2006; 24: 1329-31.
• Sengupta PP, Northfelt DW, Gentile F, et al. Trastuzumab- induced cardiotoxicity: heart failure at the crossroads. Mayo Clin Proc 2008; 83: 197-03.
• Suter TM, procter M, van Veldhuisen DJ, et al. Trastuzumab- associated cardiac adverse effects in the herceptin adjuvant trial. J Clin Oncol 2007; 25: 3859-65.
• Bird BR, Swain SM: Cardiac toxicity in breast cancer survivors: review of potential cardiac problems. Clin Cancer Res 2008; 14: 14-24.
• Slordal L, Spigset O. Heart failure induced by non-cardiac drugs. Drug Saf 2006; 29: 567-86.
• Floyd JD, Nguyen DT, Lobins RL, Bashir Q, Doll DC, Perry MC. Cardiotoxicity of cancer therapy. J Clin Oncol 2005; 23: 7685-96.
• Yeh ET, Tong AT, Lenihan DJ, et al. Cardiovascular complications of cancer therapy: diagnosis, pathogenesis, and management. Circulation 2004; 109: 3122-31.
• Saif MW, Shah MM, Shah AR. Fluoropyrimidine-associated cardiotoxicity: revisited. Expert Opin Drug Saf 2009; 8: 191-202.
• Schimmel KJ, Richel DJ, Van den Brink RB, Guchelaar HJ. Cardiotoxicity of cytotoxic drugs. Cancer Treat Rev 2004; 30: 181-91.
• Çeliker A. Meme kanserli hastalarda adjuvan kemoterapiye bağlı sol ventrikül disfonksiyonunun Troponin T ile erken dönemde tahmin edilmesi. 20. Ulusal Kardiyoloji Kong. Sözlü Bildiri. 2004.
• Mathew P, Suarez W, Kip K, et al. Is there a potential role for serum cardiac troponin I as a marker for myocardial dysfunction in pediatric patients receiving anthracycline-based therapy? A pilot study. Cancer Invest 2001; 19: 352-9.
• Herman EH, Lipshultz SE, Rifai N, et al. Cardiac troponin T: elevated serum levels and loss from cardiac myocytes in doxorubicin toxicity. Circulation 1996; 94: 1-85
• Elbl L, Hrstkova H, Chaloupka V. The late consequences of anthracycline treatment on left ventricular function after treatment for childhood cancer. Eur J Pediatr 2003; 162: 690-6.
• Sorensen K, Levitt GA, Bull C, Dorup I, Sullivan ID. Late anthracycline cardiotoxicity after childhood cancer: a prospective longitudinal study. Cancer 2003; 97: 1991-8.
• Klewer SE, Goldberg SJ, Donnerstein RL, Berg RA, Hutter JJ. Dobutamine stress chocardiography:a sensitive indicator of diminished myocardial function in asymptomatic doxorubicin- treated longterm survivors of childhood cancer. J Am Coll Cardiol 1992; 19: 394-01.
• Jurcut R, Ganame J, D’hooge J. Detection and monitoring of cardiotoxicity-what does modern cardiology offer? Support Care Cancer (2008) 16:437-45.
• Neilan TG, Jassal DS, Perez-SanzTM, Raher MJ, Tissue Doppler imaging predicts left ventricular dysfunction and mortality in a murine model of cardiac injury. Eur Heart J 2006; 27: 1868-75
• Tassan-Mangina S, Codorean D, Metivier M, Tissue Doppler imaging and conventional echocardiography after anthracycline treatment in adults: early and late alterations of left ventricular function during a prospective study. Eur J Echocardiogr 2006; 7(2): 141-6.
• Ganame J, Claus P, Eyskens B, Uyttebroeck A, Renard M, Acute cardiac functional and morphological changes after anthracycline infusions in children. Am J Cardiol 2007; 99: 974-7.
• Ganame J, Claus P, Uyttebroeck A, Renard M, D’hooge J, Myocardial dysfunction late after low dose anthracycline treatment in asymptomatic pediatric patients. J Am Soc Echocardiogr 2007; 12: 1351-8.
• Hamada H, Ohkubo T, Maeda M, Ogawa S. Evaluation of cardiac reserved function by high-dose dobutamine-stress echocardiography in asymptomatic anthracycline-treated survivors of childhood cancer. Pediatrics International 2006; 48: 313-20.
• Swain SM, Whaley FS, Ewer MS Congestive heart failure in patients treated with doxorubicin: a retrospective analysis of three trials. Cancer 2003; 97(11): 2869-79.
• Kondo C, Fukushima K, Kusakabe K. Measurement of left ventricular volumes and ejection fraction by quantitative gated SPET, contrast ventriculography and magnetic resonance imaging: a meta-analysis. Eur J Nucl Med Mol Imaging 2003; 30: 851-8.
• Chen B, Peng X, Pentassuglia L, Lim CC, Sawyer DB. Molecular and cellular mechanisms of anthracycline cardiotoxicity. Cardiovasc Toxicol 2007; 7: 114-21
• Audrey H Wu.. Cardiotoxic drugs: clinical monitoring and decision making The Heart 2008; 94: 1503-9.